Introduction {#Sec1}
============

Diabetes mellitus (DM) is one of the most significant health problems worldwide. It is a metabolic disorder in which elevated blood sugar levels are present as a result of the inability to produce a sufficient amount of insulin (type 1) or because of cellular insulin resistance (type 2). Both types of diabetes are associated with hyperglycaemia, oxidative stress, inflammation and macrovascular (coronary artery disease, atherosclerosis, hypertension and stroke) and microvascular complications such as retinopathy, nephropathy and neuropathy \[[@CR1]\].

The number of patients with diabetes mellitus is rapidly increasing every year. Global mortality resulting from diabetes in adults was estimated to be 1.5 million deaths in 2012 (World Health Organization). It is estimated that there will be 418 million patients with impaired glucose tolerance and 380 million patients with T2DM by 2025 \[[@CR2]\].

Diabetic retinopathy (DR) is a leading cause of visual impairment in patients at productive age. These alarming numbers highlight the necessity of optimization of diagnostic methods that will allow early identification of diabetic patients with significantly elevated risk of DR development that will help start optimal prevention and intervention. DR has an overall prevalence of 22--37 % in individuals with known diabetes. It leads to damage of the retina microvasculature as a result of prolonged exposure to metabolic changes induced by diabetes. If left untreated, it may lead to blindness on account of continuous blood leakage due to the loss of retinal pericytes and fenestration \[[@CR1]\]. DR is classified into two categories based on severity, namely less-severe nonproliferative diabetic retinopathy (NPDR) and severe proliferative diabetic retinopathy (PDR). The key changes of the retina in NPDR, as a result of hypoxia and venous bleading, are microaneurysms, vascular leakage, hard exudates, intraretinal microvascular abnormalities and cotton wool spots (Fig. [1](#Fig1){ref-type="fig"}). Retinal neovascularization induced by ischemia is the main characteristic of PDR \[[@CR3]\].

Fig. 1Symptoms and pathological processies typical for diabetic retinopathy leading to vision lost. *EBM* endothelial basal membrane, *BRB* blood retinal barrier, *EC* endothelial cell

The aetiology of this complex disease remains unclear and poorly understood. It is associated with both environmental and genetic factors. The possibility of developing and progression of DR is closely related to the duration of DM \[[@CR1]\]. Almost all patients with T1DM and \>60 % of patients with T2DM are anticipated to have some type of retinopathy within the first 10 years of diabetes being diagnosed. The Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) clinical trials have also confirmed significant association between chronic hyperglycaemia and development and progression of DR, however, the fundamentals of how hyperglycaemia causes microvascular changes in the retina has not been fully elucidated \[[@CR4]\]. Involvement of several biochemical pathways which can elucidate the role of hyperglycaemia in DR pathophysiology has been proposed, including activation of diacyl-glycerol **(**DAG)-PKC pathway, accelerated formation of advanced glycation endproducts (AGE), increased polyol pathway flux, increased expression of growth factors (VEGF, IGF-1), haemodynamic changes, renin-angiotensine-aldosterone system (RAAS), leukostasis, subclinical inflammation, and oxidative stress that leads to increased expression of several proinflammatory genes (NF-κB, TGF-β, NOX4, Nrf2, etc.). Other risk contributors for DR development are dyslipidemia \[[@CR5]\] and possibly blood pressure, but studies are contradictory about these risk modifiers \[[@CR4], [@CR6]\]. Pathways contributing to DR pathologies alongside with relevant genes are summarized in Fig. [2](#Fig2){ref-type="fig"}. In summary, increased vascular permeability, haemostatic abnormalities, endothelial dysfunction, increased tissue ischemia, angiogenesis and neovascularization is typical for overall DR pathophysiology \[[@CR1]\].

Fig. 2Putative roles of genes identified by candidate genes studies in pathophysiological processies during diabetic retinopathy. *RAAS* renin--angiotensin--aldosterone system, *AGE* advanced glycation end-product, *IO* intraoccular, *EBM* endothelial basal membrane, *BRB* blood retinal barrier

Genetic aspects of the diabetic retinopathy {#Sec2}
===========================================

The above mentioned risk factors are not solely responsible for susceptibility to DR. Clinical studies have revealed considerable variations in the retinopathy onset and severity that cannot be fully explained by known risk factors such as the duration of diabetes, the level of glycemic control, or concomitant vascular disease \[[@CR7]\]. For instance, some people might have DR even when they have good glycemic control and duration of DM is short. In contrast, other patients have poor glycemic control and prolonged duration of DM and yet may not develop DR. The probability of DR development also depends on the ethnicity; the Hispanics, the individuals of African descent and the Asians are more susceptible to DR \[[@CR8], [@CR9]\]. A study from 2008 reported retinopathy symptoms, including retinal microaneurysms, in nondiabetic patients with an optimal glucose level (glycosylated haemoglobin levels \<5.0 %) \[[@CR10]\] and these microvascular changes were indistinguishable from lesions in diabetic DR. Therefore there is evidence that additional risk factors and genetic predispositions have a part in the development and progression of DR and that these factors are independent of DM.

This is a solid confirmation of genetic contribution to the development and progression of DR. Over the past several years, progress has been made in identifying some of the susceptibility loci associated with DR through twin studies, family studies, candidate gene studies, linkage studies and small-scale GWAS (genome-wide association study). Twin and family studies have demonstrated that risk of DR emergence is three times higher for patients with a family history of DR than in patients without it for both T1DM and T2DM. Concordance is dramatically higher among monozygotic twins when compared to dizygotic twins \[[@CR11]\]. One of the first twin studies has reported DR concordance of 68 % in T1DM and 95 % in T2DM \[[@CR12]\]. Heritability score increases with the severity of DR, and has been estimated to be 18 and 52 % for DR and PDR, respectively \[[@CR13]\].

Candidate genes studies {#Sec3}
=======================

Our knowledge of pathophysiology of DR allows us to propose possible candidate genes, which could play a role in the development and progression of DR. Candidate gene studies compare the frequency of a particular genetic variant in subjects with or without DR. This approach has revealed several genes with a possible key role in DR. These genes are part of different physiological and pathophysiological processes in organism, often associated with inflammation, such as RAAS (renin--angiotensine--aldosterone system), glucose induced pathways, remodeling of extracellular matrix (ECM), vascular endothelial dysfunction, and angiogenesis. It has been proposed that a great number of factors and genes with modest effect, as a part of different biochemical pathways, invoke pathological processes leading to DR.

Polyol pathway and its role in DR {#Sec4}
=================================

Polyol pathway represents the main metabolic link between hyperglycaemia and damages caused by DM. Aldose reductase (ALR2) is the essentialenzyme in the pathway. ALR2 converts glucose to sorbitol in an NADPH-dependent reaction. During the hyperglycaemia sorbitol accumulates in cells and induces osmotic stress and cellular damage. The above mentioned process leads to the destruction of retinal cells, microaneurysms, thickening of the basement membrane and loss of pericytes in animal models, which are also typical symptoms of DR in humans \[[@CR14]\]. Three DR-associated ALR2 polymorphisms have been identified in different populations (see Table [1](#Tab1){ref-type="table"}). The first polymorphism located at the 5′ end of the gene, the Z-2 allele of the (CA)~n~ microsatellite located at the 5′ end of the gene increases risk of DR. In contrast, Z + 2 and Z alleles show protective effect against DR \[[@CR15]\]. Another polymorphism, rs759853, has shown association with DR where T allele confers protection against DR in T1DM \[[@CR15], [@CR16]\]. However, the use of AKR (aldo--keto reductase) inhibitors did not confirm expected results in clinical trials and they could not prevent progression of the disease \[[@CR17]\]. But these clinical trials disregarded the genetic variants in the *AKR2* gene which could have had negative impact on the function of AKR inhibitors. Another enzyme in the polyol pathway, sorbitol dehydrogenase (SDH) converts sorbitol into fructose in NAD^+^-dependent reaction. Amano et al. found that *SDH* overexpression potentiated glucose toxicity to cultured retinal pericytes, thus leading to acceleration of pericyte loss, a typical trait of DR \[[@CR18]\]. Polymorphisms rs2055858 and rs3759890 were identified in Polish, Japanese and Caucasian-Brazilian population and it is possible that they could affect the promoter activity of the *SDH* gene and have role in onset of DR \[[@CR18], [@CR19]\].

Table 1Summary of genes identified by candidate genes studies with possible role in pathophysiology of DRGene symbolGene nameFunction/cellular rolePolymorphismCh.Type of DMPopulationCommentsRef.AKR1B1/ALR2Aldose reductase genePolyol pathway---conversion of glucose to sorbitolrs35839483 \[(CA)n dinucleotide repeats\]71 and 2Chinese, Japanese, Indians, Chileans, Braziliansz-2 microsatellite confers risk in all DR, z2 microsatellite against all DR\[[@CR20]--[@CR27]\]rs759853 (c. C-106T)72Euro-Brazilian, Mainland Chinese, Han Chinese, JapaneseT allele protective against DR but according to some studies it is weak association\[[@CR25], [@CR26], [@CR28]--[@CR30]\]rs964088372AustralianAssociation with onset of diabetes\[[@CR25]\]SDHSorbitol dehydrogenasePolyol pathway---conversion of sorbitol to fructosers2055858 (c. C-1214G)152PolandWeak associations; polymorphism possibly affect promoter activity\[[@CR18], [@CR19]\]rs3759890 (c. G-888C)152Japan, Poland, Caucasian-BraziliansInconsistent finding, polymorphism possibly affect promoter activity\[[@CR18], [@CR31]\]ALDH2Mitochondrial aldehyde dehydrogenase 2Polyol pathway---transformation from acetaldehyde to acetic acid, prevents creation of AGEALDH2\*2122JapaneseAssociated with protective effect against DR\[[@CR32]\]VEGFVascular endothelial growth factorStimulation of angiogenesis and vasculogenesisrs2010963 (c. C-634G)62Japanese, Indian, CaucasianC allele confers risk for NPDR in T2DM\[[@CR33]--[@CR41]\](c. C-460T)61 and 2CaucasianPossible association with DR\[[@CR42], [@CR43]\]rs2564862Multi-ethnicT allele increase risk of DR but finding inconsistent\[[@CR33], [@CR34], [@CR37]\]rs1570360 (c. A-116G)62Multi-ethnicInconsistent finding\[[@CR33], [@CR34], [@CR42]\]rs309503962Multi-ethnicT allele increase risk of DR but finding inconsistent\[[@CR33]--[@CR36]\]rs3556939461 and 2Multi-ethnic(− 2549) DEL increases risk but finding inconsistent\[[@CR33]\]rs699947(c. A-2578C)62Multi-ethnicA allele increases risk but finding inconsistent\[[@CR33], [@CR36], [@CR40], [@CR43]--[@CR46]\]rs13207351 (c. A-152G)61 and 2CaucasianAssociated with PDR in some of the studies\[[@CR34], [@CR42], [@CR46]\]rs735286 (c. C4618T)61 and 2CaucasianHaplotype-tagged SNP associated with severity of DR\[[@CR42]\]rs2146323 (c. C5092A)61 and 2CaucasianHaplotype-tagged SNP associated with severity of DR, associated with early progression of DR\[[@CR42], [@CR44], [@CR47]\]rs833061 (c. C-1498T)62ChineseInconsistent finding and weak association\[[@CR34], [@CR37], [@CR39], [@CR46]\]rs302502162ChineseInconclusive\[[@CR33], [@CR46]\]rs1043461 and 21 and 2CaucasianG allele associated with blinding DR\[[@CR33]\]rs83306861 and 2CaucasianG allele confers risk in DR\[[@CR33]\]rs83307061JapaneseAssociated with early progression of DR but weak association\[[@CR44]\]rs3025039 (c. C+936T)62CaucasianT allele increases risk\[[@CR48]\]bFGF/FGF2Basic fibroblast growth factor/fibroblast growth factor 2Stimulation of angiogenesis and tissue repairrs4145604442Multi-ethnicA allele increases risk but weak associations\[[@CR15]\]rs30839542Multi-ethnicG allele increases risk but finding inconsistent\[[@CR15]\]c. C-754G42SlovakC allele increases level of bFGF\[[@CR49]\]c. T − 553 A\
c. T−834A42CaucasianAT genotype could be risk factor for PDR during T2DM\[[@CR50]\]IGF-1Insulin-like growth factor 1Stimulation of cell growth and proliferation, inhibition of apoptosis(CA)n42Southern Indian18-repeat of (CA) increases risk of DR\[[@CR51]\]EPOErythropoietinControl of erythropoiesis, stimulation of proliferation, migration and angiogenesis in hypoxic cellsrs1617640, rs507392, rs55123871 and 2Multi-ethnic, European American, AustralianTTA allele associated with PDR in European American, meta-analysis hasn´t found significant association; GCC haplotype associated with DR in Australian\[[@CR15], [@CR52], [@CR53]\]RAGEAdvanced glycosylation end product-specific receptorActivation of pro-inflammatory genesrs1800624 (c. T-374A)62Indian, Chinese, African-Brazilian, Caucasian - ScandinavianInconsistent finding and weak association, may be interacting with glycosylated hemoglobin\[[@CR15], [@CR54]--[@CR56]\]rs1800625 (c. T-429C)62Caucasian, Indians, DanishInconsistent finding and weak association, functional studies show differences in polymorphic receptor activity\[[@CR55]--[@CR60]\]rs2070600 (p. G82S)62Caucasian, Indian, Chinese, MalaysianAssociated with DR, no association in Malaysian\[[@CR15], [@CR58], [@CR61]\]ACE IAngiotensin-I converting enzymeComponent of the renin-angiotensin system---activation of angiotensin IIrs4646994 (c. G2350A)-INS/DEL at intron 16171 and 2Caucasian - Slovene, Danish; Japanese, Multi-ethnic, Iranian, Japanese, Chinese, PakistaniD allele possibly associated with DR in T2DM in Chinese, but inconsistent\
finding and weak association in other populations, associated with NPDR in Pakistani\[[@CR62]--[@CR66]\]GSTT1Glutathione S-transferase T1Detoxifying enzyme---conjugation of reduced glutathione to a compoundsNull genotype222Caucasian - SlovenianGreater risk of DR\[[@CR67]\]GSTM1Glutathione S-transferase M1Detoxifying enzyme---conjugation of reduced glutathione to a compoundsNull genotype12Caucasian - SlovenianLower risk of DR\[[@CR67]\]SOD2/MnSODMitochondrial manganese superoxide dismutaseDecrease of ROS production (transformation to to peroxide and oxide)rs4880 (c. C47T, p. A16V)61 and 2Slovene (Caucasian), Finnish, IndianC allele reduces risk of DR, not confirmed in Indian population\[[@CR15], [@CR36], [@CR56], [@CR65], [@CR68], [@CR69]\]eNOS3Endothelial nitric oxide synthasesSynthesis of nitric oxide (vasodilatation)rs3138808 (27 VNTR intron 4 a/b)72Indians, West African, Caucasian - Brazilian4a allele protective effect against DR\[[@CR15], [@CR37], [@CR70]--[@CR73]\]rs1799983 (c. C894T)72Caucasian---Brazilian, Danish, Multi-ethnicG allele increases risk but weak association\[[@CR15], [@CR37], [@CR50], [@CR60], [@CR72], [@CR74]\]rs41322052 (c. T-784C)71&2Caucasian---Brazilian, Multi-ethnicInconsistent finding and weak association\[[@CR37], [@CR71], [@CR72], [@CR75]\]rs2297518 (c. G-954C)72CaucasianProtective factor against NPDR\[[@CR48]\]RXRARetinoid X receptor alphaNuclear receptor---retinoic acid-mediated gene activation\
(antoxidants properties)rs313230091African AmericanAssociated with progression of DR\[[@CR76], [@CR77]\]RXRGRetinoid X receptor gammanuclear receptor---retinoic acid-mediated gene (antiproliferative effects)rs38185699TaiwaneseG allele associated with development of DR\[[@CR78]\]UCP1Uncoupling protein-1Mitochondrial anion carrier protein (thermogenesis), protection againt oxidative stressrs1800592 (c. A-3826G)41 and 2Brazilian, Chinese, DanishG allele associated with increased risk of PDR\[[@CR60], [@CR75], [@CR79]\]UCP2Uncoupling protein-2Mitochondrial anion carrier protein (thermogenesis), control of ROS productionrs660339 (p. A55V, 45 bp INS/DEL)111 and 2BrazilianRisk factor for PDR\[[@CR77], [@CR80]\]TLR4Toll-like receptor 4Pathogen recognition and activation of innate immunityrs10759931, rs192791492Indian, ChineseA,T alleles positively modulate the risk of DR, rs1927914 associated with susceptibility to DR in a Han Chinese population\[[@CR3], [@CR55]\]rs4986790, rs4986791 (p. D299G)92PolishG allele associated with early onset of DR\[[@CR81]\]CFHComplement factor HRegulator of complement activationrs800292 (p. I62V)12ChineseAssociated with DR\[[@CR82]\]CFBComplement factor BRegulator of complement activationrs104870962ChineseAssociated with DR\[[@CR82], [@CR83]\]MCP-1/CCL2Monocyte chemoattractant protein-1Cytokine---activation of monocytes, macrophages and lymphocytesrs1024611 (c. A-2518G)172Chinese, Korean, JapaneseG allele associated with susceptibility to DR and specifically PDR in Koreans\[[@CR84]--[@CR86]\]TGF-β1Transforming growth factor-beta 1Control of cell growth, proliferation, differentiation and apoptosisc. T869C (p. L10P)192Multi-ethnicPotential protect factor against DR\[[@CR15], [@CR83]\]c. G915C (p. R25P)192SlovakStrong risk factor for PDR\[[@CR87]\]ICAM1Intercellular adhesion molecule 1Stabilization of cell--cell interactions and facilitation of leukocyte endothelial transmigrationrs13306430192Multi-ethnicG allele confers protection\[[@CR15], [@CR77]\]rs5498 (p. K469E)192Chinese, Indian, Japanese, Caucasian - SloveneInconsistent finding, discrepancy maybe caused by ethnicities\[[@CR55], [@CR88]--[@CR93]\]SLC2A1/GLUT1Solute carrier family 2, member 1Transport of glucose across the plasma membranesrs841846 (c. A26177G)11 and 2African American, MalaysianSignificant associations with severe DR, associated with progression of DR, not confirmed in Malaysian\[[@CR77], [@CR94]\]rs84185311Malaysian, Multi-ethnicWeak association\[[@CR77], [@CR94]\]SLC2A11Solute carrier family 2, member 11Transport of glucose across the plasma membranesrs4822441221African AmericanAssociated with progression of DR\[[@CR77]\]SLC24A3Solute carrier family 24, member 3Sodium-calcium exchangerrs2294895201African AmericanAssociated with progression of DR\[[@CR77]\]PPARγPeroxisome proliferator-activated receptor γNuclear receptor---regulation of fatty acid storage and glucose metabolism, role in vascular permeability, inflammation, angiogenesis, neovascularization, and insulin resistancers1801282 (c. C34G, p. P12A)31 and 2Caucasian - Poland; Chinese, Danish, Multi-ethnicG allele confers protection against DR in Caucasian but finding inconsistent - protective effect against only PDR during T2DM in Pakistan population, not for Asian patients\[[@CR60], [@CR79], [@CR95], [@CR96]\]rs1051041931African AmericanAssociated with progression of DR\[[@CR15], [@CR95]\]TCF7L2/TCF4Transcription factor 7-like 2Transcription factor for several genes (Wnt signaling pathway), vascular developmentrs7903146, rs7901695, rs12255372102Caucasian---Italian, Chinese, Multi-ethnicAssociated with DR, cardiovascular disease and coronary artery disease, rs7903146 associated with DR risk in Caucasian\[[@CR15], [@CR79], [@CR96]--[@CR98]\]OPG/OCIFOsteoprotegerin/osteoclastogenesis inhibitory factorCytokine receptorrs2073618, rs313406982Caucasian - SlovenianCA haplotype increase risk of DR\[[@CR99]\]PAI-1Plasminogen activator inhibitor-1Serine protease inhibitor---inhibitor of plasminogen activation, tissue repair and remodelingrs1799768 (4G/5G INS/DEL)72Indian, Caucasian, Euro-Brazilian, Multi-ethnic, Pakistani4G/5G allele increases risk but finding inconsistent, ethnicity discrepancies\[[@CR28], [@CR55], [@CR66], [@CR100], [@CR101]\]MMP-2Matrix metalloproteinase-2Breakdown of extracellular matrixc. C-1306T162ChineseT allele associated with PDR\[[@CR7]\]ANGPT1Angiopoietin 1Vascular development and angiogenesisrs128364981African AmericanSignificant associations with severe DR\[[@CR77]\]APOEApolipoprotein ETransportation of lipoproteins, fat-soluble vitamins, and cholesterolE2/E3/E4191 and 2Mexicans, Multi-ethnicInconsistent finding and weak association\[[@CR102], [@CR103]\]BBS2Bardet-Biedl syndrome 2 proteinUnknown function and link to DRrs4784675161African AmericanSignificant associations with severe DR\[[@CR15]\]CPVL/CHN2Carboxypeptidase, vitellogenic-like; chimerin 2Carboxypeptidase---unknown function/regulation of a cell growth, proliferation, and migrationrs3905972ChineseIncreases risk of DR, significant in meta-analysis\[[@CR77], [@CR104]\]rs100263072TaiwaneseAssociated with DR and NPDR\[[@CR142]\]CTSHCathepsin HLysosomal cysteine proteinase - degradation of lysosomal proteins, putative role in microcirculation changesrs3825932151DanishT allele associated with reduced risk of progression to PDR\[[@CR60]\]DRD2Dopamine receptor D2Dopamine receptor---regulation of vasodilatation, aldosterone production and insulin secretionrs7131056111African AmericanSignificant associations with severe DR\[[@CR77]\]EDN1Endothelin-1Vasoconstrictionrs5370 (p. K198N)62ChineseReduced risk in Chinese\[[@CR77], [@CR105]\]ENPP1Ectonucleotide pyrophosphatase/phosphodiesterase 1Insulin resistance, interaction with integrinsrs140918161African AmericanSignificant associations with severe DR\[[@CR77]\]ERBB3/HER3Human epidermal growth factor receptor 3Protein-tyrosine kinase---activation of downstream signaling pathways, unknown link to DRrs2292239121DanishT allele associated with reduced risk of progression to PDR\[[@CR60]\]FLT1/VEGFR1FMS-like tyrosine kinase 1/vascular endothelial growth factor receptor 1Protein-tyrosine kinase---control of cell proliferation and differentiationrs622227131African AmericanAssociated with progression of DR\[[@CR77]\]FRMD3FERM domain containing 3Maintaining cellular shape, putative TSG, unknown link to DRrs1086802592ChineseWeak association with DR\[[@CR104]\]HLA-BMajor histocompatibility complex, class I, BRegulation of the immune system---presenting peptides on the cell surfacers252360861African AmericanSignificant associations with severe DR, associated with progression of DR\[[@CR77]\]HTR1BSerotonin receptor 1BGPCR for serotonin---regulation of the serotonin, dopamine, and acetylcholine release, putative regulator of retinal blood flowrs122881461African AmericanSignificant associations with severe DR\[[@CR77]\]HTRA1/ARMS2HtrA serine peptidase 1/age-related maculopathy susceptibility 2Serine protease---regulation of insulin-like growth factors, putative regulator of cell growth and neovascularizationrs11200638, rs10490924102IndianMarginal association with DR\[[@CR55]\]IL-10Interleukin-10Cytokine---pleiotropic effects in immunoregulation and inflammationn. A-1082G12IndianG allele is risk factor for PDR\[[@CR113]\]INSRInsulin receptorActivation of the insulin signaling pathwayrs10500204191African AmericanAssociated with progression of DR\[[@CR77]\]ITGA2B1Integrin α2β1Cell--cell and cell-extracellular matrix interactionsRFLP - Bgl II5/102Japanese, CaucasianRisk factor for DR\[[@CR15], [@CR106], [@CR143]\]ITGB5Integrin β5Cell--cell and cell-extracellular matrix interactionsrs986535931African AmericanAssociated with progression of DR\[[@CR15]\]MTHFRMethylenetetrahydrofolate reductaseRemethylation of homocysteine to methioniners1801133 (c. C677T)12Japanese, Euro-Brazilian, Multi-ethnic, TurkishControversial findings, T allele possible increases risk of DR because of hyperhomocysteinemia\[[@CR28], [@CR77], [@CR107], [@CR108]\]NPYNeuropeptide Y (p. L7P)Vasoconstriction, angiogenesisrs1613972FinnishC allele increases risk but weak association\[[@CR144]\]OLR1Oxidited low-density lipoprotein (lectin-like) receptor 1Recognition, internalization and degradation of oxidized low-density lipoprotein, putative regulator of Fas-induced apoptosisrs2742115121African AmericanAssociated with progression of DR\[[@CR77]\]PEDF/SERPINF1Pigment epithelium derived factor/serpin peptidase inhibitor, clade F member 1 (alpha-2 antiplasmin)Antioxidative properties, inhibition of angiogenesis, neurotrophic factor (neuronal differentiation in retinoblastoma cells)rs12150053, rs12948385, rs8697961, rs1126287172Multi-ethnicNot associated with DR\[[@CR8], [@CR15]\]PON1Paraoxonase 1Cellular antioxidant---inhibition of HDL oxidationrs662 (p. Q192R)72Multi-ethnicInconsistent finding and weak association\[[@CR15], [@CR109]\]rs854560 (p. L55M)71 and 2Multi-ethnicAssociated with DR\[[@CR109]\]PON2Paraoxonase 2Cellular antioxidant, hydrolytic activity---a putative role in defense responses to pathogenic bacteriars7493 (p. S311C)71 and 2Multi-ethnicInconsistent and weak association\[[@CR77]\]s12026 (p. A148G)71 and 2Multi-ethnicInconsistent and weak association\[[@CR109]\]PROS1Protein SCofactor for the anticoagulant proteasers1306235531African AmericanSignificant associations with severe DR\[[@CR77]\]PSMD9Proteasome 6S subunit, non-ATPase, 9Part of multicatalytic proteinase complex (proteasome)rs74421874, rs14259, rs3825172122ItalianAssociated with DR\[[@CR110]\]ROBO2Roundabout, axon guidance receptor, homologue 2Axon guidance and cell migration, unknown link to DRrs1086555931African AmericanSignificant associations with severe DR\[[@CR77]\]ROCK2Rho-associated, coiled-coil containing protein kinase 2Serine/threonine kinase---regulation of cytokinesis, smooth muscle contraction, the formation of actin stress fibers and focal adhesions, and the activation of the c-fos serum response elementp. T431N, p. R83K21 and 2TurkishNo association\[[@CR15], [@CR111]\]Romo-1Reactive oxygen species modulator 1Mitochondrial membrane protein---increase of the level of reactive oxygen species in cellsrs6060566202CaucasianIndependent risk factor for DR\[[@CR112]\]TFTransferrinTransportation iron from the intestine, reticuloendothelial system, and liver parenchymal cells to all proliferating cells in the bodyrs381164731Associated with progression of DR\[[@CR77]\]TNF-αTumor necrosis factor-alfaMultifunctional proinflammatory cytokine (cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation)rs361525 (c. G-238A), rs1800629 (c. G-308A), rs1799724 (c. C-857T)62Indian, Caucasian - BraziliansAA genotype of rs361525 confers risk for pathogenesis of PDR in Indian, rs1800629 associated with PDR in Caucasian - Brazilians\[[@CR113]--[@CR115]\]TNF-β/LTATumor necrosis factor-beta (lymphotoxin-alpha)Cytokine--- inflammatory, immunostimulatory, and antiviral responses, the formation of secondary lymphoid organs, apoptosisNcoI62Caucasian - Slovakβ2 allele is genetic factor for incidence of PDR in T2DM\[[@CR15], [@CR116]\](GT)n microsatellite62Asian IndianAllele 4 (103 bp) is a low risk for developing retinopathy, allele 8 (111 bp) is associated with PDR\[[@CR114], [@CR115]\]VDRVitamin D receptorNuclear hormone receptor for vitamin D3, associated with insulin secretion and sensitivity, anti-proliferative and anti-angiogenic effect, regulator of apoptosesrs10735810121 and 2Multi-ethnicT allele increases risk but weak association\[[@CR15]\]rs2228570122Han ChineseT allele increases risk of DR onset\[[@CR117]\]rs1544410122Polish, KoreanProtective effect against DR in Korean\[[@CR118], [@CR119]\]*Ch*. chromoseme, *Ref*. references, *Multi-ethnic* findings of studies regardless of ethnicity or from meta-analyses, *TSG* tumor suppressor gene, *GPCR* G protein-coupled receptor

The mitochondrial aldehyde dehydrogenase 2 (ALDH2), expressed in vasculature, detoxifies reactive aldehydes formed from glucose and lipids, also prevents creation of AGE (advanced glycation end products) \[[@CR32]\]. Morita et al. have reported a substantial relation between the *ALDH2*\**2* allele and the incidence of DR in their study.

Growth factors with role in DR {#Sec5}
==============================

Vascular endothelial growth factor (VEGF) is one of the major factors in angiogenesis and influences vascular permeability of endothelial cells. VEGF is activated by microvascular changes induced by hypoxia during DM and also by hyperglycaemia \[[@CR120]\]. Activation of VEGF leads to the destruction of the blood retinal barrier (BRB), the development of diabetic macular oedema and neovascularization typical for PDR. At the same time, elevated serum and vitreous levels of VEGF have also been described in eyes of patients with PDR \[[@CR121]\]. Anti-VEGF therapies have led to the improvement of the patients´ condition and to the deceleration of retinal vessels proliferation \[[@CR122]\]. Studies have revealed several polymorphisms in the *VEGF* promoter (rs2010963, rs25648, rs1570360, rs3095039, rs35569394, rs699947, rs13207351, rs735286, rs2146323, rs833061, rs302502, rs10434, rs833068 and rs833070) with possible associations with DR \[[@CR15], [@CR33], [@CR42], [@CR44]\]. Rs2010963 (−634C/G) has been associated with DR in Japanese and Indian populations \[[@CR34], [@CR35]\] whereas G allele of rs2010963 has significant protective effect against NPDR in patients with T2DM. Rs2010963 is also associated with higher risk of macular oedema in Japanese population \[[@CR123]\]. There are constantly emerging studies identifying new polymorphisms in *VEGF* gene with possible connections to DR which underlines importance of this gene in the development of DR.

Other growth factors with a possible function in the pathology of DR are the basic fibroblast growth factor (bFGF) and insulin-like growth factor 1 (IGF-1). The bFGF is important for tissue repair and is angiogenic factor. Studies have revealed increased level of bFGF in patients with PDR and it seems to stimulate VEGF production. IGF-1 regulates the proliferation and differentiation of several cell types. Levels of intravitreal IGF-1 were found to be significantly increased in the eyes of patients with PDR compared to those of controls \[[@CR124]\]. Variants identified to date are summarized in the Table [1](#Tab1){ref-type="table"}.

Erythropoietin (EPO) plays an important role in stimulation of bone marrow stem cells, erythropoiesis, proliferation, migration, and angiogenesis in hypoxic vascular endothelial cellsStudy has reported a elevated concentration of EPO in the vitreous of DM and PDR patients compared to controls \[[@CR52]\]. There are two studies which have reported the association of rs1617640, rs507392, and rs551238 with the development of DR, but these studies report different findings. Tong et al. have determined the TTA haplotype as a risk contributor in European American population, whereas Abhary et al. have associated the GCC haplotype with DR in Australian population \[[@CR52], [@CR53]\].

Interaction of various growth factors, cytokines, cell signalling molecules and extracellular matrix are essential for angiogenesis during DR \[[@CR125]\] while VEGF plays crucial part \[[@CR126]\] (Fig. [3](#Fig3){ref-type="fig"}).

Fig. 3Genes harboring DNA polymorphisms involved in angiogenesis during diabetic retinopathy (DR). *AS* angiostatin, *ES* endostatin, *BRB* blood retinal barrier, *ECM* extracellular matrix, • inhibition

Receptor for advanced glycation end products and cytokines {#Sec6}
==========================================================

Hyperglycaemia causes nonenzymatic glycation of proteins and lipids and the creation of AGE. Accumulation of AGE leads to tissue damage by the formation of a covalent crosslinks between proteins, which alter structure and function of proteins. Another feature of AGE is its ability to interact with different surface receptors, such as the receptor for advanced glycation end products (RAGE). RAGE is a immunoglobulin and its activation leads to cytokine secretion. Cytokines accelerate the advance of diabetic complications by supporting proinflammatory processes and increasing endothelial permeability \[[@CR127]\]. AGEs are found in the retinal vessels of diabetic patients where their levels correlate with those in the serum as well as with severity of retinopathy \[[@CR128]\]. The c. T--374A (rs1800624), p. Gly82Ser (rs2070600) and c. T-429C (rs1800625) polymorphisms in the RAGE gene are associated with DR in Caucasians and Asian Indians \[[@CR54], [@CR57], [@CR129], [@CR130]\], but the association was not confirmed in Chinese \[[@CR131]\].

Dysregulation of RAAS system {#Sec7}
============================

The rennin-angiotensin-aldosterone system (RAAS) is an endocrine system involved in the regulation of blood pressure and fluid balance. Patients with diabetes show dysregulation of RAAS system, namely angiotensin converting enzymes I and II (ACEI, ACEII) and angiotensin receptors which are upregulated in retina during PDR independently of blood pressure \[[@CR132]\]. ACE converts angiotensin I (ATI) to angiotensin II (ATII) which mediates its haemodynamic effects through the angiotensin receptor ANGTR1 and ANGTR2. ATII in the eye regulates promotion of capillary growth, cell growth, intraocular blood flow and pressure,, enhances vascular permeability, increases oxidative stress and via the expression of several growth factors including VEGF, IGF-1 and PDGF \[[@CR15]\]. ACE inhibitors, angiotensin receptor blockers prevents neovascularization, reduce the incidence and progression of DR in T1DM. Studies have proposed that *ACEII* is also involved in PKC activation \[[@CR133]\]. Meta-analysis suggested that *ACE* I/D polymorphism (insertion/deletion of a 287 bp Alu sequence in intron 16) may be associated with PDR \[[@CR62]\].

The other polymorphisms modulating risk of DR {#Sec8}
=============================================

The retina is very sensitive to damage by oxidative stress. Oxidative stress is strongly implicated in the pathogenesis of DR, therefore the role of detoxifying enzymes, such as glutathione S-transferases (GST), was considered in the development of DR. Studies have shown that *GSTT1*-null genotype is found more frequently in the cases with DR in Caucasians patients with T2DM compared to controls, so the *GSTT1*-null genotype can be a risk factor for DR The individuals homozygous for the *GSTT1*-null allele had more generalized vasculopathy that leads to increased risk of sight threatening DR. In contrast, the *GSTM1*-null genotype may confer protection against development of DR in people with T2DM \[[@CR67]\], but at the same time this polymorphism confers elevated risk for lung cancer \[[@CR134]\]. There are reports that deficiency in GSTM1 leads to slower excretion of isothiocyanates. Isothiocyanates also suppress expression of VEGF which is the main inductor of retinal neovascularization in diabetes \[[@CR67]\].

Oxidative stress induces a large amount of ROS and is assumed to damage the mitochondrial DNA. Mitochondrial manganese superoxide dismutase (*MnSOD*) prevents an excessive production of ROS by dismutation of superoxide radicals into hydrogen peroxide and hence defends the retinal endothelial cells from oxidative damage. The polymorphism rs4880 (c. C47T, p. A16V) affects a mitochondrial processing efficiency under oxidative stress and has been associated with DR in some studies \[[@CR36], [@CR68], [@CR69]\].

Regarding PDR, presence of the 4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (*eNOS*) has been associated with 3.4 times increased risk of PDR in Caucasian patients with T2DM \[[@CR135]\]. In contrast, other studies have proposed that the 4a allele has a protective effect against DR \[[@CR70], [@CR71]\]. NO synthesized by eNOS is an endogenous vasodilator and has a role in induction of angiogenesis and regulation of VEGF expression. NO levels are significantly elevated in PDR patients relative to nondiabetic subject.

A study in 2008 revealed that retinoid-X receptor alpha (RXRA) possessess antioxidants properties and is associated with the development of DR \[[@CR76]\]. Polymorphism rs3132300 has been linked with a progression of DR in T2DM in African American population. Also, polymorphism rs3818569 of the retinoid-X receptor gamma (*RXRG*) has been found to be connected with an increased DR risk in the Taiwanese population \[[@CR78]\].

Uncoupling protein 1 (UCP 1) is the mitochondrial inner membrane electron carrier that has a part in protection against oxidative stress. It has been proposed that *UCP 1* and its product play role in insulin resistance when oxidative stress pathways are activated. SNP rs1800592, which is located in the promoter of the *UCP1*, has been shown to be associated with glucose homeostasis, adiposity and obesity, as well as changes in the body mass index (BMI) and body weight, resulting from metabolic disorders. UCP 1 has been implicated as a candidate marker for a risk factor of DR and the rs1800592 (c. A-3826G) polymorphism has been associated with PDR \[[@CR75], [@CR79]\]. Uncoupling protein 2 (UCP2) regulates production of reactive oxygen species (ROS) by mitochondria. Overproduction of ROS is associated with diabetic retinopathy (DR), thereby UCP2 gene polymorphisms can be involved in the development of this complication. rs660339 can be a relevant risk factor associated with PDR in both type 2 and 1 of diabetes \[[@CR77], [@CR80]\].

The inflammatory processes are a major part of the DR pathophysiology. They are often regulated by inadequate activation of members of the immune system. Toll-like receptor 4 (TLR4) takes part in the activation of a pro-inflammatory response by the ligand-depended activation of the nuclear factor-κB (NF-κB) pathway. Any deregulation of *TLR4* signaling due to single nucleotide polymorphisms (SNPs) in the extracellular domain of *TLR4* may alter the ligand binding capacity and hence disturb the balance of pro- and anti-inflammatory cytokines \[[@CR81]\]. It has been reported that rs4986790, rs4986791, rs10759931 and rs1927914 in TLR4 positively modulate the risk of DR \[[@CR3], [@CR81], [@CR136]\].

There is increasing evidence from in vitro and in vivo studies that suggests a pathogenic role of the complement system in the development of diabetic angiopathy. In these studies, increased expression of several complement factors, namely, complement factor H (CFH), complement factor B (CFB), component 3 (C3), and component 5 (C5), has been observed in the vitreous of DR patients. CFH and CFB (an antagonist of CFH) contribute to the regulation of the activation of complement cascade. Polymorphism rs800292 (p.I62V) in *CFH* affects protein-binding affinity with C3b and subsequently activation of the complement alternative pathway. A synergy effect between *CFH* rs800292 and *CFB* rs1048709 conferring a significantly increased risk for DR has been identified in the study of Wang \[[@CR82]\].

Studies have reported significantly increased levels of monocyte chemotactic protein 1 (MCP-1) in aqueous and vitreous conditions in DR patients. MCP-1 has an ability to activate monocytes, macrophages and lymphocytes. Hyperglycaemia accelerates MCP-1 production in vascular endothelial cells and retinal epithelial cells which can lead to neovascularization and increased permeability of retinal vessels typical for PDR. Moreover rs1024611 polymorphism has been associated with DR in the Japanese, Korean, and Chinese populations \[[@CR84]--[@CR86]\].

Transforming growth factor β1 (*TGF-β1*) has an important role in angiogenesis, endothelial cell proliferation, adhesion and the deposition of extracellular matrix. The *TGF-β1* gene may be involved in the development of DR through induction of angiogenesis and BRB breakdown. C. T869C (p. L10P) polymorphism has been associated with a protective effect against DR \[[@CR15], [@CR83]\].

Intercellular adhesion molecule-1 (*ICAM-1*) has a major role in mediating the adhesion of circulating leukocytes to the blood vessel wall and transendothelial migration to the vascular intima. The increased retinal expression of *ICAM-1* is thought to play a key role in leukostasis-mediated BRB breakdown, capillary occlusion and endothelial cell damage in DR \[[@CR88]\]. Polymorphisms of *ICAM-1* gene might have a role in modulation of its own gene expression but findings about p. K469E polymorphism (rs5498) are inconsistent across multiple studies \[[@CR55], [@CR88]--[@CR91]\]. The G allele of rs13306430 could confer protection against DR in T2DM patients \[[@CR15]\].

Solute carrier family 2(*SLC2A1)*, also known as facilitated glucose transporter (*GLUT1*) is expressed in endothelial cells of the BRB where SLC2A1 is the prevalent glucose transporter. Functional loss of BRB is typical for DR and studies have shown that patients with DR have high expression of *GLUT1* in endothelial cells. *SLC2A1* c. A26177G polymorphism has been associated with DR in a study of Ng \[[@CR94]\].

The role of peroxisome proliferator-activated receptor γ (*PPARγ*) in DR pathogenesis has come to forefront mainly because of the protein's role in vascular permeability, inflammation, angiogenesis, neovascularization, and insulin resistance, all of which contribute to the onset and severity of DR. However, the studies describing associations of *PPARγ* polymorphisms and DR have been inconsistent \[[@CR15], [@CR95]\].

Transcription factor 7-like 2 (*TCF7L2*/*TCF4*) is a key component in the regulation of fundamental processes such as vascular development. It has been found to mediate pathological neovascularization in PDR. Common variant rs7903146 in *TCF7L2* has been reported to be strongly associated with T2DM and also with PDR in Caucasian \[[@CR96]\]. An Italian study observed associations between *TCF7L2* variants (rs7903146, rs7901695 and rs12255372) and DR, cardiovascular disease and coronary artery disease \[[@CR97]\].

Osteoprotegerin (OPG), also called the osteoclastogenesis inhibitory factor (OCIF), is an important regulatory molecule in the vasculature. Rs2073618, rs3134069 polymorphisms have been linked with DR \[[@CR99]\].

Plasminogen activator inhibitor-1 (*PAI-1*) is an inhibitor of plasminogen activation and is involved in tissue repair and remodeling. PAI-1 plays a crucial part in the regulation of intravascular fibrinolysis which is part of DR pathophysiology. Studies have investigated the connection between *PAI-1* 4G/5G and DR risk but findings have been inconsistent, maybe due to ethnicity discrepancies \[[@CR15], [@CR100], [@CR101]\].

Matrix metalloproteinases (MMPs) are proteolytic enzymes that degrade extracellular matrix (ECM) components. MMPs also regulate cell proliferation, neovasculogenesis and tissue remodelling because degradation of the extracellular matrix (ECM) proteins of the basement membrane is necessary for endothelial cells to migrate, proliferate, and to form capillaries. Increased expression of MMP-2 may expedite degradation of the type IV collagen and the gap junction protein, accelerating the vascular complications of diabetes. It has been reported that c. C-1306T polymorphism seems to be genetic susceptibility factor for the development of DR \[[@CR7]\].

In this review, we discussed candidate genes and polymorphisms with the highest genetic association with DR, or those most frequently analysed in studies in different population. The other genes and their polymorphisms associated with DR are summarized in Table [1](#Tab1){ref-type="table"} in alphabetical order. Studies concerning these genes have reported very weak or borderline associations, had small sample sizes and most of them have failed replication in other populations \[[@CR137]\]. We did not include studies and polymorphisms that have been done on only one population and showed no associations with DR. None of the polymorphisms identified by candidate gene studies have achieved widespread acceptance as a marker of high risk of diabetic retinopathy. In part, this may be because of the complexity of DR which probably has more multifactorial, polygenic and environmental contributors to its pathophysiology.

In our review, we have included a number of genes in which multiple alleles or nearby SNPs have varying strengths of association or significance in relation to diabetic retinopathy. Possible explanation for this is variable association between the SNPs themselves with the causative change depended also on populations.

Another one of the possible reasons for the setback of the gene candidate approach is focusing on single SNPs when the linkage disequilibrium does not have to manifest \[[@CR16]\]. It would be potentially useful to focus on haplotypes associated with DR instead of solely on SNPs. In addition, insufficient sample sizes to detect the modest effect of polymorphisms, incomplete coverage of variation in candidate genes and incorrect hypotheses about genes in the pathophysiology of DR are some of the reasons for controversial success of candidate genes studies. Based on these weaknesses of standard candidate gene studies, two recent studies have examined a higher number of candidate genes for DR in sample sizes larger than those used previously, in an approach that mimics a genome-wide approach \[[@CR77], [@CR138]\]. The first study, which examined 193 candidate genes with DR of type 1 diabetic African-Americans, found genetic associations in 13 genes with progression of DR and the polymorphisms are listed in Table [1](#Tab1){ref-type="table"} \[[@CR77]\]. Identified genes are involved in pathways related to glucose metabolism, inflammatory processes, angiogenesis/vascular permeability, insulin signalling, retinal development, or blood pressure regulation. The second study, the Candidate gene Association Resource (CARe) has not confirmed connection between previously associated gene from numerous previous independent studies and DR \[[@CR138]\]. The most interesting findings from this study are the variants in the P-selectin (*SELP*) (rs6128) and in the iduronidase (rs6856425) that have shown to be significantly linked with DR in European Americans, but were not seen in African-Americans, Hispanic Americans, or Asian Americans.

It is possible that the potential success of candidate gene studies lies in better characterization and definition of clinical phenotypes of DR, represented by specific patterns of severity and progression of DR. Only then, studies of candidate genes are worth pursuing, involving appropriately well-defined subgroups of patients \[[@CR139]\]. Furthermore, it would be worthwhile to expand studies to those genes mutations in which are known to initiate hyperglycaemia \[[@CR140]\] and indirectly lead to development of DM and DR.

Conclusion {#Sec9}
==========

DR remains to be one of the most complex, heterogeneous, multifactorial disorders in any genetic studies. It is one of the leading causes of blindness and visual impairment in the world and treatments options are limited. Research worldwide is focused on understanding the pathogenic mechanisms in DR with the key goal to prevent this disease and developing new drugs for treatments. There is a common consensus that the susceptibility to DR is contingent to a great amount of relatively common allelic variants with a modest effect, and how these genes interact among themselves and with environmental influences. Each of the allelic variants increased risk of DR by a small portion in overall susceptibility. The identification of genetic susceptibility loci for DR by genetic studies has not proved notably successful thus far, given the often contradictory and inconclusive results. It is obvious that the study of the DR genetics is still poorly developed and stands against numerous challenges. The most common approaches in studying this complex disease are insufficient for elucidating pathology of DR. At the same time, most studies of new possible treatments disregarded genetic background of the patietns, which could contribute to the treatment setback. Possible new NextGen sequencing methods and approaches based on interconnection of various omics, such as genomics, especially pharmacogenetics, transcriptomics, proteomics and metabolomics, will bring new breakthrough findings in the future. At this time, we can surely state that there is a long way ahead to fully understand this complex disease.
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